Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Lowers Price Target to $42
Benzinga Newsdesk 22 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and lowers the price target from $43 to $42.
Morgan Stanley analyst Sean Laaman maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and lowers the price target from $43 to $42.